11. November 2009 05:29
New Mayo Clinic research studied the association between prostate-specific antigen (PSA) levels and prostate size and found that routine annual evaluation of prostate growth is not necessarily a predictor for the development of prostate cancer. However the study suggests that if a man's PSA level is rising quickly, a prostate biopsy is reasonable to determine if he has prostate cancer.
[More]
10. November 2009 07:40
Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced the initiation of a Phase 1/2 clinical trial of its lead candidate TOK-001 for the treatment of patients with castration resistant prostate cancer (CRPC). TOK-001 is the only compound in development that combines three distinct mechanisms of action for the treatment of CRPC.
[More]
7. November 2009 00:23
Researchers at Wake Forest University School of Medicine and the University of Wisconsin-Madison have discovered that some elevated prostate-specific antigen (PSA) levels in men may be caused by a hormone normally occurring in the body, and are not necessarily a predictor of the need for a prostate biopsy.
[More]
80bd1ed3-155a-42e5-b7f0-6e43ecce9ad4|1|4.0
Posted in: Men's Health News
Tags: Biopsy, Calcium, Cancer, Cell, Hospital, Impotence, Incontinence, Nutrition, Obesity, Prostate Cancer, Prostate-Specific Antigen, Urinary Incontinence
6. November 2009 00:25
The November issue of European Urology, the official journal of the European Association of Urology, features an article focussing on prostate specific antigen (PSA) velocity and early cancer detection. It has been suggested that changes in PSA over time aid prostate cancer detection.
[More]
4. November 2009 23:14
Researchers in the Oregon Health & Science University Knight Cancer Institute and the Portland Veterans Affairs Medical Center have found a combination of radiation therapy and chemotherapy given before prostate removal is safe and may have the potential to reduce cancer recurrence and improve patient survival.
[More]
c63fd5e2-7723-4840-ad87-bcfb0d534ee4|0|.0
Posted in: Men's Health News
Tags: Cancer, Chemotherapy, Docetaxel, Education, Hormonal Therapy, Oncology, Prostate Cancer, Prostate-Specific Antigen, Radiation Therapy, Radiology, Urology, Veterans Affairs
4. November 2009 03:30
The American Urological Association (AUA) is aware of recent news reports disparaging prostate cancer testing. We are concerned that these reports are causing significant confusion for patients and we wish to clarify our recommendations on prostate cancer testing with the prostate-specific antigen (PSA) test and digital rectal exam (DRE). The AUA strongly supports early prostate cancer detection and feels it is in a man's best interest to consider being tested for prostate cancer.
[More]
29. October 2009 07:52
Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced that detailed data from its open-label Phase 2 clinical study of PRX302 in patients with moderate to severe benign prostatic hyperplasia (BPH) will be presented at the 30th World Congress of the Société Internationale d'Urologie Conference.
[More]
27. October 2009 08:16
Astellas Pharma Inc. ("Astellas") and Medivation, Inc. announced today that they have entered into a global agreement to develop and commercialize MDV3100, Medivation's investigational drug for the treatment of prostate cancer.
[More]
16036dfe-9ac1-49da-b708-20a11f8a5a5f|0|.0
Posted in: Business / Finance | Pharmaceutical News
Tags: Alzheimer's Disease, Bone, Cancer, Cell, Chemotherapy, Diabetes, DNA, Docetaxel, Immunology, Lung Cancer, Oncology, Pfizer, Prostate Cancer, Prostate-Specific Antigen, Skin Cancer, Testosterone, Urology, Virus
21. October 2009 05:33
Twenty years of screening for breast and prostate cancer - the most diagnosed cancer for women and men - have not brought the anticipated decline in deaths from these diseases, argue experts from the University of California, San Francisco and the University of Texas Health Science Center at San Antonio in an opinion piece published in the "Journal of the American Medical Association."
[More]
7a13af5e-0aac-4dce-b102-ef61adea7675|0|.0
Posted in: Men's Health News | Medical Condition News | Women's Health News
Tags: Biopsy, Breast Cancer, Cancer, Colon Cancer, Education, Finasteride, Hematology, Lung Cancer, Oncology, Pathology, Prostate Cancer, Prostate-Specific Antigen, Psychology, Radiology, Urology
19. October 2009 10:22
Daxor Corporation, a medical instrumentation and biotechnology company, today announced the receipt of a signed trial agreement from the Institute for Medical Research at the Durham Veterans Affairs (VA) Medical Center of Durham, North Carolina.
[More]
1. October 2009 00:39
When it comes to the prostate cancer, the disease known as the "silent killer" because it often exhibits no symptoms, to be forewarned is to be forearmed. It is the second leading cancer killer in men, just behind lung cancer. Every year, more than 218,000 men are diagnosed with prostate cancer in the United States, claiming about 28,000 lives.
[More]
29. September 2009 04:52
Men largely make decisions about prostate cancer screening based on conversations with their clinicians, but these discussions often do not include information about the risks of testing in addition to the benefits, according to a report in the September 28 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
[More]
29. September 2009 03:42
The largest single-institution study of its kind has found few complications in prostate cancer patients treated with radiotherapy after surgery to remove the prostate. Men in this study received radiotherapy after a prostate-specific antigen (PSA) test following surgery indicated their cancer had recurred.
[More]
24. September 2009 02:27
Medivation, Inc. (Nasdaq: MDVN) today announced treatment of the first patient in a Phase 3 clinical trial of the investigational drug MDV3100 in advanced prostate cancer. Known as AFFIRM, the trial will evaluate the novel androgen receptor antagonist MDV3100 in men with castration-resistant prostate cancer who were previously treated with docetaxel-based chemotherapy.
[More]
232f4c67-ab03-4913-9aa2-9efecc6304a5|1|5.0
Posted in: Men's Health News | Drug Trial News | Medical Condition News
Tags: Alzheimer's Disease, Bone, Cancer, Cell, Chemotherapy, DNA, Docetaxel, Lung Cancer, Pfizer, Prostate Cancer, Prostate-Specific Antigen, Skin Cancer, Testosterone
22. September 2009 07:06
Research and Markets (http://www.researchandmarkets.com/research/f2ffa1/current_and_emergi) has announced the addition of the "Current and Emerging Cancer Diagnostic Tests: Emerging Assays and Companies Developing New Technologies and Products" report to their offering.
[More] 
Subscribe